NCT04649359 2026-05-19MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbPfizerPhase 2 Active not recruiting187 enrolled 14 charts 1 FDA